CytoMed Therapeutics Limited Ordinary Shares (GDTC)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, consistent earning power, and a margin of safety. CytoMed is none of those things yet. It is a clinical-stage biopharmaceutical company with 42 employees, developing cell-based immunotherapies. Its lead candidate, CTM-N2D, is in Phase I trials, which means the science is unproven and the cash flows are hypothetical. The financials confirm the risk: the FairStock figures show a negative P/E of -3.22, a P/B of 2.02, ROE of -50.28%, and ROCE of -29.31% based on the 2026-10-13 close. The Piotroski F-Score is 0/9, a stark sign of weak fundamental momentum. On the positive side, debt is low with D/E of 0.07, and the Altman Z-Score of 3.29 suggests the balance sheet is not immediately distressed. But a low-debt, cash-burning biotech can still destroy equity if trials fail or financing dries up. The market cap is only $11.6M, and the stock trades at $0.87, near the low end of its 52-week range of $0.68 to $3.68. FairStock's Lynch category is 'none' because there are only zero years of filed results, so there is no track record to classify. Valuation is almost impossible in Graham terms: no earnings, no revenue growth data, and P/B above 1 means we are paying up for intangible pipeline hopes. I would call this a speculative option on clinical success, not a value investment. Without a margin of safety from earnings or assets, it belongs in the 'too hard' pile for a disciplined value investor.

In plain English: CytoMed Therapeutics is a tiny clinical-stage biotech trying to develop cell-based treatments for cancer and degenerative diseases. The data shows it is losing money, with no revenue or profit growth figures and very weak profitability measures. Because there are no earnings to value it on, the share price is not a classic bargain on these numbers; it is a speculative bet on its early-stage science.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer